Pristiq has been on the market for approximately 15 years, having received U.S. Food and Drug Administration (FDA) approval in June 2007 [1].
When did Pristiq first get approved?
Pristiq, also known by its generic name desvenlafaxine, was approved by the FDA on June 29, 2007 [1]. It is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder [2].
What is the patent status of Pristiq?
The patent for Pristiq has faced challenges and expirations. Information regarding specific patent expiry dates and any associated litigation can be found on resources like DrugPatentWatch.com [3].
How is Pristiq manufactured and approved?
Pristiq is manufactured by Viatris Inc. [1]. The drug's approval followed clinical trials demonstrating its efficacy and safety for treating major depressive disorder [2].
What are the alternatives to Pristiq for depression?
Other medications for major depressive disorder include different classes of antidepressants such as selective serotonin reuptake inhibitors (SSRIs), other SNRIs, and tricyclic antidepressants (TCAs) [4]. The choice of medication often depends on individual patient factors, including symptom severity, potential side effects, and other medical conditions [4].
What is the generic version of Pristiq called?
The generic name for Pristiq is desvenlafaxine [2]. Generic versions can become available after the expiration of patents protecting the brand-name drug [3].
Sources:
1. https://www.accessdata.fda.gov/drugsatfdadocs/appletter/2007/021960s000,021961s000,021962s000,021963s000,021964s000l.pdf
2. https://www.accessdata.fda.gov/drugsatfdadocs/label/2008/021960s008lbl.pdf
3. https://www.drugpatentwatch.com/
4. https://www.mayoclinic.org/diseases-conditions/depression/diagnosis-treatment/drc-20356013